Cathay Drug

The Cathay Drug Co., Inc.
Corporation
Industry Pharmaceutical
Founded 1952
Founder Yao Shiong Shio and family
Headquarters Vernida I Condominium 120 Amorsolo Street, Legazpi Village, Makati, Philippines
Key people
 Yao Shiong Shio
Website cathaydrug.ph

The Cathay Drug Company, Inc. (CDCI) is a Philippine pharmaceutical company based in Makati.

History

Cathay Drug was founded in 1952 by the family of Yao Shiong Shio, a widely known postwar industrialist and president of the Filipino-Chinese Chambers of Commerce and Industry in 1974 to 1976.[1] From 1952 to 2000, Cathay Drug Company has been the exclusive distributor of pharmaceutical and animal health products from American company Merck Co., which is known outside the United States and Canada as Merck Sharp and Dohme.

Operations

The Cathay Drug Company operates exclusively in the Philippines. Its main area of specialization is the marketing and distribution of pharmaceutical drugs and products for both humans and animals. The company acquires its products through licensing agreements with domestic and international firms. Among its main suppliers are the following:

Reception

Cathay Drug is recognized as one of the fastest-growing pharmaceutical companies in the Philippines. In 2012, it was included in the Top 20 Leading Philippine Pharmaceutical Companies based on Value in the Philippine Pharmaceutical Industry Audit [2] for ethical segment by IMS. It was also ranked second among national pharmaceutical companies for ethical segment.

Symposium

In a symposium organized by The Cathay Drug Co Inc and Zambon Italy, four international and two local doctors presented the latest available guidelines in UTI management to local specialists. During the symposium, Dr. George Zhanel of the University of Manitoba (Canada) Faculty of Medicine discussed antibiotic resistance in relation to UTI. Dr. Andrea Novelli of the University Hospital Careggi (Italy) gave an overview of antibiotics therapy. Professor Nicola Petrosillo of Lazzaro Spallanzani (National Institute for Infectious Diseases, Italy) spoke about the stewardship of community and hospital-acquired infections. Dr. Kurt Naber of the Technical University of Munich (Germany) presented international UTI treatment guidelines. Dr. Ricardo Manalastas, Jr. of the University of the Philippines (UP) College of Medicine tackled UTI in relation to pregnancy and menopause. Dr. Edsel Salvana of the National Institute of Health, UP Manila presented local UTI treatment guidelines.

Introduced at the event was Monurol (Fosfomycin Trometamol), a unique and highly effective treatment positioned as a first line antibiotic treatment for UTI and acute cystitis (inflammation/infection of the urinary bladder). The novelty is its single dose regimen that assures excellent patient compliance. It also has extremely low global antibiotic resistance rates, assuring its effectiveness and the prompt relief of symptoms. A one-time, one-dose regimen is unique to the drug, as it maintains a very high urinary concentration for more than 72 hours after a single dose. This compares with common antibiotics that must be taken twice a day for seven to 14 days, depending on the severity of the infection.

[3]

References

  1. ↑ Flores, W.L. (2006-05-08). "Who will be the next taipans?". Philstar. Retrieved 2016-06-27.
  2. ↑ "Philippine Pharmaceutical Industry Factbook, 8th Edition, August 2012" (PDF). Philippine Pharmaceutical Industry. Retrieved 27 June 2016.
  3. ↑ "Increase in UTI patient compliance seen with breakthrough single-dose antibiotic". Milette Sison. Retrieved 24 July 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.